X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Viracta's lead program (VRx-3996) evaluates the all-oral combination of nanatinostat, its proprietary investigational drug, and valganciclovir in a Phase 2 clinical trial for the treatment of EBV-positive relapsed/refractory (R/R) lymphoma.
Lead Product(s): Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area: Oncology Product Name: VRx-3996
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Viracta Therapeutics
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Merger February 24, 2021
Details:
The merger will focus on the advancement and expansion of Viracta’s clinical stage, precision oncology pipeline including Viracta’s lead program of all-oral combination of nanatinostat and valganciclovir to teat Epstein-Barr virus-positive relapsed/refractory lymphomas.
Lead Product(s): Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area: Oncology Product Name: VRx-3996
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Viracta Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger November 30, 2020
Details:
Abstract titled "PDK1 inhibitor SNS-510 shows synergy with standard cancer therapies in solid tumor and hematologic cancer models " will be presented at the conference.
Lead Product(s): SNS-510
Therapeutic Area: Oncology Product Name: SNS-510
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2020
Details:
Sunesis anticipates using the net proceeds from the proposed offering to fund ongoing development of PDK1 inhibitor SNS-510 and general corporate purposes.
Lead Product(s): SNS-510
Therapeutic Area: Oncology Product Name: SNS-510
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oppenheimer & Co. Inc.
Deal Size: $12.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 28, 2020
Details:
The changes will extend Sunesis's cash runway and provide it with the necessary resources to execute on its PDK1 program evaluating its PDK1 inhibitor SNS-510, while also allowing the flexibility to explore opportunities for additional value creation.
Lead Product(s): SNS-510
Therapeutic Area: Oncology Product Name: SNS-510
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2020
Details:
Company will not advance its non-covalent BTK inhibitor vecabrutinib into the planned Phase 2 portion of the Phase 1b/2 trial in adults with relapsed/refractory chronic lymphocytic leukemia and other B-cell malignancies.
Lead Product(s): Vecabrutinib
Therapeutic Area: Oncology Product Name: SNS-062
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
